Devising Biocompatible, NIR-Activated Helical Pyroptosis Agents via π-Twisting Strategy for Promoting Antitumor Immunity
By
Shi, XQ (Shi, Xiaoqian) [1] ; Wang, YM (Wang, Yaming) [1] ; Qi, F (Qi, Fan) [1] ; Zhang, H (Zhang, Hao) [1] ; Cao, YH (Cao, Yahui) [1] ; Xu, XN (Xu, Xiaona) [1] ; Liu, WQ (Liu, Weiqing) [1] ; Li, CH (Li, Changhua) [1]
(provided by Clarivate)
Volume
20Issue
49
DOI
10.1002/smll.202405496
Article Number
2405496
Published
DEC 2024
Indexed
2024-12-15
Document Type
Article
Jump to
Abstract
Specifically controlling cell pyroptosis is advantageous for oncotherapy as it allows simultaneous ablation of primary tumors and activation of immunogenicity of tumor environment. Herein, a facile and robust strategy is presented to construct efficient NIR-activated helical pyroptosis agents (PyroAs) with negligible dark cytotoxicity. It is demonstrated that the construction of four intramolecular B-X bonds (X = O or N) within the BODIPY chromophore enforces a significant twisting of its pi-conjugation, yielding a variety of helical HBD molecules with desired high photosensitivity and negligible dark toxicity. A robust approach is established to extend HBD into the near-infrared (NIR) region through site-selective incorporation of an electron-withdrawing ester moiety. It is also proved that targeted delivery of the NIR-activated HBD-ER to the endoplasmic reticulum (ER) specifically activates pyroptosis pathway by equipping it with an ER-targeting moiety. Finally, the favorable biocompatibility, excellent antitumor efficacy, and remarkable systematic immune response of this unique NIR-activated helical PyroAs are shown in vivo, demonstrating its potential application in solid tumor immunotherapy.